New rapid test could speed up diagnosis of deadly blood clotting disorder
NCT ID NCT05046717
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is testing a new, faster blood test for diagnosing acquired thrombotic thrombocytopenic purpura (aTTP), a rare but life-threatening blood clotting disorder. The new test, called HemosIL AcuStar, will be compared to two existing tests in 500 patients from Spain and Portugal. The goal is to see if it can diagnose severe ADAMTS13 deficiency more quickly and accurately, which could help doctors start life-saving treatment sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ADAMTS13 activity test (HemosIL AcuStar chemiluminescent assay)
- What this could lead to
- If successful, this could lead to faster and more accurate diagnosis of TTP, helping doctors start the right treatment sooner and potentially saving lives.
- What could go wrong
- This is a diagnostic validation study, not a treatment trial. The new test may not prove significantly better than existing methods, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centro Hospitalar e Universitario de Coimbra
Coimbra, Coimbra District, 3004-561, Portugal
-
Complejo Hospitalario Universitario A Coruña
A Coruña, A Coruña, 15006, Spain
-
Hospital Clinic de Barcelona
Barcelona, Spain
-
Hospital Clínico San Carlos
Madrid, Spain
-
Hospital Gregorio Marañon
Madrid, Spain
-
Hospital La Fe de Valencia
Valencia, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.